Daiichi Sankyo has announced that Japanese regulators have approved its Inavir laninamivir octanoate hydrate DPI for the prevention of the flu. In August 2012, the company had announced positive Phase 3 results for that indication. The inhaler was approved for treatment of the flu in Japan in October 2010.
The company said that it “has great expectations for the additional influenza prevention indication for Inavir, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society.”
Read the Daiichi Sankyo press release.
